Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Tuberculosis
•
Pulmonology
•
Pulmonary Infections
What is your approach to prescribing RIPE for 6 month vs rifapentine/moxifloxacin for 4 months in the treatment of drug sensitive TB in the US?
Related Questions
What is the interpretation of two IGRAs with negative mitogen wells, in the absence of immunosuppression?
How would you approach treatment of latent TB for patients who cannot tolerate rifamycins or isoniazid due to allergy, intolerance, or drug-drug interactions?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
What is the interpretation of an IGRA with positive TB wells and negative nil and negative mitogen wells?
Are there clinical scenarios in which you would start empiric treatment for pulmonary TB without microbiologic confirmation?
Which biomarkers or diagnostic tools do you prioritize to support the decision to start antifungal treatment in septic patients with no clear source of infection but at high risk for fungal infections?
What is your approach to counseling patients regarding re-initiation of anti-TNF therapy after completion of treatment for non-disseminated pulmonary histoplasmosis?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
Do you administer prophylactic antibiotics to prevent VAP following intubation in patients with acute brain injury?
Do add a macrolide for immunomodulatory effect in patients with macrolide-resistant M. abscessus?
